We’re a cut above the rest.

Final Cut Consulting provides expertise in Next Generation Sequencing (NGS) data to aid drug discovery and development. We can help you across all steps of the process, from experimental design to higher-order analysis to advising on regulatory strategy around your data.

We have experience with analyzing next-generation sequencing data across immuno-oncology, neurology, regenerative medicine, and hematology indications. We integrate large-data analysis, core biological domain expertise, and knowledge of the competitive and regulatory landscape to provide a comprehensive picture on your data.

We will have an initial information-gathering meeting with your team in order to determine the scope of our services. If you have data that needs analyzing, we’ll work to transfer a copy of your data into Final Cut Consulting’s AWS account where it will be analyzed with our state-of-the-art pipelines. The final deliverable will be a report of actionable insights on your data.

If your desired services don’t entail data analysis (e.g. review of regulatory strategy or design of experiments), we will provide a thorough review of the landscape to ensure that your approach yields the most productive outcomes possible.

The 21st century is the century of biology. Since the completion of the human genome project in 2003, our capabilities in drug development, diagnostics, and precision medicine have exponentially expanded. Gene editing technologies such as CRISPR-Cas9 have brought a “revolution within a revolution” - DNA can now be read, then edited, then proofread.

Presently, we are able to generate data faster than we can think about it all. Furthermore, with the sheer magnitude of data at our disposal, it can be difficult to discern signal from noise. This is where we come in.

We envision a data-driven world where our journey towards global human prosperity is accelerated by insights hiding right under our noses - in the plethora of data that we all hold. It just takes a step in the right direction.